公开(公告)号：US20240360071A1

公开(公告)日：2024-10-31

申请号：US18386906

申请日：2023-11-03

Applicant: Orphalan S.A.

Inventor： Timothy James Morley ,  Ronnie Maxwell Lawrence ,  Naseem Amin

IPC: C07C211/14 ,  A61K9/00 ,  C07C209/84

CPC classification number: C07C211/14 ,  C07C209/84 ,  A61K9/0053 ,  C07B2200/13

Abstract: The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1° 2θ and Raman shifts 943, 1173, 1527 and 1612±5 cm−1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.

公开(公告)号：US20240358635A1

公开(公告)日：2024-10-31

申请号：US17744864

申请日：2022-05-16

Applicant: Soteria Battery Innovation Group, Inc.

Inventor： Brian G. Morin ,  Carl C. Hu ,  Drew J. Pereira

IPC: A61K9/00 ,  A61K9/127 ,  A61K31/353 ,  A61K31/704 ,  A61K47/69 ,  A61P1/16

CPC classification number: A61K9/0053 ,  A61K9/0019 ,  A61K9/127 ,  A61K9/1271 ,  A61K31/353 ,  A61K31/704 ,  A61K47/6911 ,  A61P1/16

Abstract: A constrained, wound lithium-ion battery cell with an internal fuse component that exhibits significant improvements in terms of life cycle times is provided. Disclosed herein are lithium-ion battery structures and configurations utilizing at least one thin metallized film current collector that provides safety features with low thermal runaway potential, low internal resistance, and high thermal conductivity with a simplified manner of providing external electrical conductivity simultaneously. The provision of a highly constrained and wound structure thereof unexpectedly allows for extended cycle life upon charging that is significantly improved in comparison with previous wound lithium-ion battery devices. A range of compression forces accords such results, with such forces permissible through various pathways, including winding curvature, number of windings within the cell housing, hardness of housing, and structural geometry therein. A method of providing long cycle life results is covered herein, as well.

公开(公告)号：US12128060B2

公开(公告)日：2024-10-29

申请号：US17842042

申请日：2022-06-16

Applicant: Elysium Health, Inc.

Inventor： Ryan Dellinger ,  Santiago Roel Santos ,  Eric A. Marcotulli ,  Daniel A. Alminana ,  Mark Morris ,  Leonard Pershing Guarente

IPC: A61K31/706 ,  A61K9/00 ,  A61K31/09 ,  A61P1/16

CPC classification number: A61K31/706 ,  A61K9/0053 ,  A61K31/09 ,  A61P1/16

Abstract: Provided herein are methods and compositions related to treating and/or preventing liver related diseases and disorders and for improving liver health in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside and/or pterostilbene.

公开(公告)号：US12128020B2

公开(公告)日：2024-10-29

申请号：US18591994

申请日：2024-02-29

Applicant: AXCESS GLOBAL SCIENCES, LLC

Inventor： Ryan Lowery ,  Jacob Wilson ,  Terry Lacore

IPC: A61K31/19 ,  A61K9/00 ,  A61K31/522 ,  A61P3/04 ,  A61P25/28

CPC classification number: A61K31/19 ,  A61K9/0053 ,  A61K31/522 ,  A61P3/04 ,  A61P25/28

Abstract: In various implementations, beta-hydroxybutyrate, related compounds, and/or one or more other compounds may be administered to an individual to cause weight loss, weight maintenance, elevate blood ketone levels, maintain blood ketone levels, reduce blood glucose levels, maintain blood glucose levels, improve energy, focus, mood, cognitive function, or aide with neurological or inflammatory disorders and/or combinations thereof.

公开(公告)号：US20240350594A1

公开(公告)日：2024-10-24

申请号：US18683423

申请日：2022-08-12

Applicant: Anagram Therapeutics, Inc.

Inventor： Alexey Margolin ,  Stefan Pierzynowski ,  Kateryna Pierzynowska

IPC: A61K38/44 ,  A61K9/00 ,  A61P3/10

CPC classification number: A61K38/443 ,  A61K9/0053 ,  A61K38/44 ,  A61P3/10 ,  C12Y101/03004 ,  C12Y111/01006

Abstract: Disclosed are pharmaceutical compositions comprising a glucose oxidase enzyme and a peroxide-degrading enzyme (e.g., a catalase enzyme), which can be used, among other things, to treat hyperglycemia, diabetes, obesity, metabolic syndrome, and/or an eating disorder.

公开(公告)号：US20240350418A1

公开(公告)日：2024-10-24

申请号：US18681298

申请日：2022-08-05

Applicant: PHARVARIS GMBH

Inventor： Christoph GIBSON

IPC: A61K9/48 ,  A61K9/00 ,  A61K31/4709

CPC classification number: A61K9/4866 ,  A61K9/4825 ,  A61K31/4709 ,  A61K9/0053

Abstract: The invention relates to pharmaceutical compositions for oral administration comprising a bradykinin (BK) B2 receptor antagonist having a chemical structure according to Formula 1, or a salt or solvate thereof, wherein R is deuterium or hydrogen: Formula (1), such as (S)-N-(1-deutero-1-(3-chloro-5-fluoro-2-((2-methyl-4-(1-methyl-1H-1,2,4-triazol-5-yl)quinolin-8-yloxy)methyl)phenyl)ethyl)-2-(difluoromethoxy)acetamide. The compositions comprise the BK B2 receptor antagonist in a dissolved form in a liquid vehicle comprising propylene glycol monocaprylate, polyoxyl castor oil, and propylene glycol. Furthermore, therapeutic uses of the compositions are provided.

公开(公告)号：US12122778B2

公开(公告)日：2024-10-22

申请号：US17277425

申请日：2019-09-19

Applicant: Novo Nordisk Health Care AG

Inventor： Xiaozhang Zheng ,  Anna Ericsson ,  Neal Green ,  Gary Gustafson ,  David R. Lancia, Jr. ,  Jian Lin ,  Lorna Mitchell ,  David Richard ,  Tatiana Shelekhin

IPC: C07D487/04 ,  A61K9/00

CPC classification number: C07D487/04 ,  A61K9/0053

Abstract: The disclosure provides novel chemical compounds useful as activators of PKR. PKR activating compounds are useful in the treatment of disease and disorders associated with modulation of PKR and/or PKM2, such as pyruvate kinase deficiency (PKD).

公开(公告)号：US12122753B2

公开(公告)日：2024-10-22

申请号：US16961230

申请日：2019-01-10

Applicant: MetrioPharm AG

Inventor： Ingo Saar ,  Wolfgang Brysch ,  Jörg von Wegerer

IPC: C07D237/32 ,  A61K47/22 ,  A61K9/00

CPC classification number: C07D237/32 ,  A61K47/22 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0053

Abstract: The present invention relates to a method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione or salts thereof, to the solubilisate produced by this method and respective uses in pharmaceutical dosage forms. A phosphatidylcholine-based solubilization method is disclosed.

公开(公告)号：US12121549B2

公开(公告)日：2024-10-22

申请号：US16642741

申请日：2017-08-29

Applicant: BGI SHENZHEN

Inventor： Zhuye Jie ,  Suisha Liang ,  Huihua Xia ,  Yuanqiang Zou ,  Liang Xiao ,  Huijue Jia

IPC: A61K35/74 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48 ,  A61K45/06 ,  A61P9/10

CPC classification number: A61K35/74 ,  A61K9/0053 ,  A61P9/10 ,  A61K9/20 ,  A61K9/48 ,  A61K45/06

Abstract: The present invention discloses an application of Alistipes shahii in preparing a composition for preventing and/or treating lipid metabolism related diseases, for example but not limited to, atherosclerosis related diseases, cardiovascular diseases and obesity.

公开(公告)号：US20240343714A1

公开(公告)日：2024-10-17

申请号：US18524947

申请日：2023-11-30

Applicant: Verastem, Inc.

Inventor： Farzaneh Seyedi

IPC: C07D405/12 ,  A61K9/00

CPC classification number: C07D405/12 ,  A61K9/0053 ,  C07B2200/13

Abstract: Solid forms of a dual RAF/MEK inhibitor, pharmaceutical compositions thereof, oral dosage forms thereof, and methods of treating cancer are described herein. Also provided herein are processes for preparing solid forms of a dual RAF/MEK inhibitor and pharmaceutical compositions and oral dosage forms thereof.